Hensify (crystalline hafnium oxide) / Nanobiotix, J&J 
Welcome,         Profile    Billing    Logout  
 1 Disease   11 Trials   11 Trials   368 News 


«12345»
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Enrollment open, Trial initiation date, Trial primary completion date, Combination therapy:  NANORAY-312: NBTXR3 With or Without Cetuximab in LA-HNSCC (clinicaltrials.gov) -  Apr 4, 2022   
    P3,  N=500, Recruiting, 
    The preliminary observed efficacy results may warrant further examination in larger clinical studies. Not yet recruiting --> Recruiting | Initiation date: Jul 2021 --> Jan 2022 | Trial primary completion date: Dec 2023 --> Jul 2024
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Journal:  Radiotherapy enhanced by NBTXR3 nanoparticles overcomes anti-PD1 resistance and evokes abscopal effects. (Pubmed Central) -  Feb 15, 2022   
    These results suggest that blockade of multiple immune checkpoints in parallel with NBTXR3-mediated radiotherapy may be effective in metastatic cancers.[Y.H. The ability of NBTXR3 to evoke significant abscopal effects in both anti-PD1-sensitive and -resistant lung cancers may open the possibility of its use for treating patients with metastatic lung cancer regardless of sensitivity (or resistance) to immunotherapies.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, J&J
    Trial completion date, Trial termination, Trial primary completion date, Combination therapy, Metastases:  A Study of PEP503(Radio-enhancer) With Radiotherapy and Chemotherapy for Patients With Rectal Cancer (clinicaltrials.gov) -  Jan 11, 2022   
    P1/2,  N=32, Terminated, 
    Initiation date: Nov 2021 --> Mar 2022 Trial completion date: Jun 2023 --> Jul 2021 | Recruiting --> Terminated | Trial primary completion date: Dec 2021 --> Jul 2021
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    [VIRTUAL] Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside (McCormick Place West, Room W179 a/b) -  Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1940;    
    P1, P2/3
    Here we demonstrate that it overcomes resistance to anti-PD-1 treatment mechanisms in mice and led to tumor regression in patients having progressed on anti-PD-1 therapy. These results highlight the potential of NBTXR3+RT to positively impact the immuno-oncology field.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    [VIRTUAL] Digital XP SH 15 - Digital XP Science Highlights 15 - Sarcoma (Digital XP) -  Oct 30, 2021 - Abstract #ASTRO2021ASTRO_1465;    
    The abstracts that will be discussed during this session are: Study of Novel Radioenhancer NBTXR3 Plus Radiotherapy in Patients with Locally Advanced Soft Tissue Sarcoma: Results of the Long-term Evaluation in the Phase II/III Act.In.Sarc Trial Radiosensitivity, Immune Activation, and Mutational Frequency of Melanoma Metastases Across Tissue Types Changes in Merkel Cell Oncoprotein Antibodies (AMERK) after Radiation Therapy (RT) in Curatively Treated Merkel Cell Carcinoma (MCC) and Association with Recurrence Radiomics analysis of fat saturated T2-weighted MRI sequences for prognostic prediction to soft-tissue sarcoma of the extremities and trunk treated with neoadjuvant radiotherapy Genomic Predictors of Recurrence Patterns in Localized Soft Tissue Sarcoma Treated with Radiation Therapy Impact of Pathological Response to Preoperative Radiotherapy in Soft Tissue Sarcoma A Phase 2 Study of 5-Day Preoperative Radiotherapy for Patients with High-Risk Primary Soft Tissue Sarcoma Factors associated with salvage amputation and radical surgery in recurrent sarcoma: a single institution retrospective review High Local Control Following Pre-Operative Radiotherapy for Adult Deep Soft Tissue Sarcoma of the Head and Neck Adult Head and Neck Rhabdomyosarcoma: Management, Outcomes, and the Impact of IMRT on Locoregional Control High Risk Head and Neck Cutaneous Squamous Cell Carcinoma Treated with Mohs Surgery or Mohs Surgery and Adjuvant Radiation Therapy High terminal hemorrhage risk from cardiac angiosarcoma brain metastases warrants frequent brain imaging and early intervention Click here to view this session on the Digital XP. Be sure to log in.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    [VIRTUAL] Digital XP SH 08 - Digital XP Science Highlights 08 - Biology (Digital XP) -  Oct 30, 2021 - Abstract #ASTRO2021ASTRO_791;    
    This Science Highlights session will showcase abstracts that are noteworthy in the field of Radiation and Cancer Biology.  The abstracts that will be discussed during this session are: A targeted gene expression risk score predicts meningioma outcomes and responses to radiotherapy Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: from bench to bedside Focal Adhesion Kinase drives resistance to therapy in HPV-negative head and neck squamous cell carcinoma in a p53-dependent manner CDK4/6 Inhibition and Radiation as a Treatment Strategy to Improve Local Disease Control in Breast Cancers with Poor Prognoses SIRT2 promotes murine melanoma progression through natural killer cell inhibition Click here to view this session on the Digital XP. Be sure to log in.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Journal, PD(L)-1 Biomarker, IO biomarker, Pan tumor:  Overcoming Resistance to Anti-PD-1 With Tumor Agnostic NBTXR3: From Bench to Bedside. (Pubmed Central) -  Oct 29, 2021   
    P1, P2/3
    Here we demonstrate that it overcomes resistance to anti-PD-1 treatment mechanisms in mice and led to tumor regression in patients having progressed on anti-PD-1 therapy. These results highlight the potential of NBTXR3+RT to positively impact the immuno-oncology field.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix, Erbitux (cetuximab) / Eli Lilly, EMD Serono
    Clinical, P1 data, Journal:  Phase I Study of Novel Radioenhancer NBTXR3 Activated by Radiotherapy in Cisplatin-Ineligible Locally Advanced HNSCC Patients. (Pubmed Central) -  Oct 29, 2021   
    P1
    NBTXR3 intratumoral administration followed by IMRT may represent an option in elderly in elderly patients or patients with multiple comorbidities with LA-HNSCC who have limited therapeutic options. NBTXR3 activated by RT showed promising anti-tumor efficacy, supporting further evaluation in a phase III randomized trial.
  • ||||||||||  Hensify (crystalline hafnium oxide) / Nanobiotix
    Dual blockade of LAG3 and TIGIT improves the treatment efficacy of a nanoparticle-mediated immunoradiation in anti-PD1 resistant lung cancer in mice (Poster Hall) -  Oct 1, 2021 - Abstract #SITC2021SITC_479;    
    Furthermore, Nanostring transcriptomic analysis of cells isolated from the tumors of mice thus treated showed evidence of classical two-step immunological priming, with an elevation of innate immune genes at the primary tumor and full-blown activation of the immune system within the secondary tumor. Conclusions Blockade of TIGIT and LAG3 with NBTXR3+XRT+aPD1 improved CD8+ T-cell proliferation, augmented the antitumor response at both irradiated and unirradiated (abscopal) tumors, and induced potent long-term antitumor memory in mice.